Ruth Stevens

Dr. Ruth Stevens has more than 20 years of experience in the development of new drugs and therapeutic agents. She has led more than 100 FDA regulatory meetings in her career and continues to lead numerous meetings. She has authored more than 70 abstracts/publications and is frequently requested as a speaker both nationally and internationally. In addition, Stevens served as an Advisory Committee Member (non-voting) to the FDA’s Blood Products Advisory Committee Meeting in 2013.

Before joining Camargo, Stevens was senior director of clinical affairs at Duramed Pharmaceuticals overseeing Phase I-IV scientific and clinical activities, with an emphasis on women’s health and HRT products. She also served as director of pharmacokinetics and pharmacodynamics at Phoenix International Life Sciences where she was responsible for scientific management of clinical pharmacology Phase I and II studies.

Stevens began her career at the FDA as a pharmacokinetic reviewer and a team leader in the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research (CDER).